1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 30, 31/Jul/2025
  4. Article
Perspective Open Access
Like 0
Download

SDG 3: hepatitis

Abstract

Drug-related infectious diseases (DRID), such as HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV), contribute to high morbidity and mortality among people who inject drugs (PWID). The European Union Drugs Agency (EUDA) is responsible for monitoring DRID and related behaviours for PWID in Europe. We updated the EUDA DRID technical protocol which covers all steps from planning to data analysis needed for a survey among PWID. Drug-related infectious disease-specific indicators were revised. To enable a more effective monitoring of the current epidemiological situation, we added specific core indicators, such as prevalence of viraemic HBV, HCV and HIV care cascades and harm reduction-related indicators. HIV pre-exposure prophylaxis and take-home naloxone were added as optional indicators. The process was informed by a European working group, who shared best-practice examples of (repeated) cross-sectional and cohort surveys using different methods in various settings. To reach the World Health Organization’s goal of ending HIV and the viral hepatitis epidemics, comprehensive DRID monitoring among the disproportionately affected PWID population is needed.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.30.2500007
2025-07-31
2025-08-05
/content/10.2807/1560-7917.ES.2025.30.30.2500007
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/30/eurosurv-30-30-4.html?itemId=/content/10.2807/1560-7917.ES.2025.30.30.2500007&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. Geneva: WHO; 2022. Available from: https://www.who.int/publications/i/item/9789240053779
  2. World Health Organization (WHO). Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. Geneva: WHO; 2022. Available from: https://www.who.int/publications/i/item/9789240052390
  3. Thomadakis C, Gountas I, Duffell E, Gountas K, Bluemel B, Seyler T, et al. Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis. Lancet Reg Health Eur. 2023;36:100792.  https://doi.org/10.1016/j.lanepe.2023.100792  PMID: 38188273 
  4. Degenhardt L, Webb P, Colledge-Frisby S, Ireland J, Wheeler A, Ottaviano S, et al. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review. Lancet Glob Health. 2023;11(5):e659-72.  https://doi.org/10.1016/S2214-109X(23)00057-8  PMID: 36996857 
  5. European Union Drugs Agency (EUDA). Viral hepatitis elimination barometer among people who inject drugs in Europe. Lisbon: EUDA; 2024. Available from: https://www.euda.europa.eu/publications/data-factsheet/viral-hepatitis-elimination-barometer-among-people-who-inject-drugs-in-europe_en
  6. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192-207.  https://doi.org/10.1016/S2214-109X(17)30375-3  PMID: 29074409 
  7. Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017;9(9):CD012021.  https://doi.org/10.1002/14651858.CD012021.pub2  PMID: 28922449 
  8. Wiessing L, Ferri M, Běláčková V, Carrieri P, Friedman SR, Folch C, et al. Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. Harm Reduct J. 2017;14(1):19.  https://doi.org/10.1186/s12954-017-0141-6  PMID: 28431584 
  9. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). DRID Guidance Module: Methods of bio-behavioural surveys on HIV and viral hepatitis in people who inject drugs — a short overview. Lisbon: EMCDDA; 2013. Available from: https://www.euda.europa.eu/publications/manuals-and-guidelines/drid-toolkit_en
  10. European Union Drugs Agency (EUDA). Best practice examples of surveys for monitoring drug-related infectious diseases in the EU/EEA: A supplement to the DRID technical protocol. Lisbon: EUDA; 2024. Available from: https://www.euda.europa.eu/publications/manuals-and-guidelines/drug-related-infectious-diseases-drid-technical-protocol_en
  11. Hope V, Jeannin A, Spencer B, Gervasoni JP, van de Laar MJ, Dubois-Arber F, et al. Mapping HIV-related behavioural surveillance among injecting drug users in Europe, 2008. Euro Surveill. 2011;16(36):19960.  https://doi.org/10.2807/ese.16.36.19960-en  PMID: 21924119 
  12. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Monitoring the elimination of viral hepatitis as a public health threat among people who inject drugs in Europe: the elimination barometer Luxembourg: Publications Office of the European Union; 2019. Available from; https://www.euda.europa.eu/publications/data-factsheet/viral-hepatitis-elimination-barometer-among-people-who-inject-drugs-in-europe_en
  13. European Union Drugs Agency (EUDA). Drug-related infectious diseases (DRID) technical protocol – surveys on HIV and viral hepatitis in people who inject drugs. Lisbon: EUDA; 2024. Available from: https://www.euda.europa.eu/publications/manuals-and-guidelines/drug-related-infectious-diseases-drid-technical-protocol_en
  14. Samartsidis P, Harris RJ, Dillon J, Desai M, Foster GR, Gunson R, et al. Evaluating the effect of direct-acting antiviral agent treatment scale-up on Hepatitis C virus prevalence among people who inject drugs in UK. Int J Drug Policy. 2024;144(Pt 1):104429.  PMID: 38942687 
  15. World Health Organization (WHO). Monitoring and evaluation for viral hepatitis B and C: recommended indicators and framework. Technical Report. Geneva: WHO; 2018. Available from: http://apps.who.int/iris/bitstream/10665/204790/1/9789241510288_eng.pdf.
  16. Hope VD, Harris RJ, Vickerman P, Platt L, Shute J, Cullen KJ, et al. A comparison of two biological markers of recent hepatitis C virus (HCV) infection: implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugs. Euro Surveill. 2018;23(47):1700635.  https://doi.org/10.2807/1560-7917.ES.2018.23.47.1700635  PMID: 30482265 
  17. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008;168(10):1099-109.  https://doi.org/10.1093/aje/kwn237  PMID: 18849303 
  18. Broady TR, Valerio H, Alavi M, Wheeler A, Silk D, Martinello M, et al. Factors associated with experiencing stigma, discrimination, and negative health care treatment among people who inject drugs. Int J Drug Policy. 2024;128:104468.  https://doi.org/10.1016/j.drugpo.2024.104468  PMID: 38795465 
  19. European Centre for Disease Prevention and Control (ECDC). Prevention measures: progress towards the elimination targets. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/assets/Prevention-Hepatitis-B-and-C/elimination-targets-progress.html#hepatitis-B-vaccination
  20. European Centre for Disease Prevention and Control (ECDC). HIV Pre-Exposure Prophylaxis in the EU/EEA and the UK: implementation, standards and monitoring. Operational guidance. Stockholm: ECDC; 2021. Available from:https://www.ecdc.europa.eu/en/publications-data/HIV-PrEP-eueea-and-uk-implementation-standards-monitoring-guidance
  21. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Drugs and Drug Addiction. Preventing fatal overdoses: a systematic review of the effectiveness of take-home naloxone. Luxembourg: Publications Office of the European Union; 2015. Available from: https://www.euda.europa.eu/publications/emcdda-papers/naloxone-effectiveness_en
Standardising monitoring data on drug-related infectious diseases among people who inject drugs in Europe – an update of the European Union Drugs Agency technical protocol, 2024
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Ida+Sperle&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sperle Ida</a>, <a href="/search?value1=Thomas+Seyler&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Seyler Thomas</a>, <a href="/search?value1=Filippo+Pericoli&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pericoli Filippo</a>, <a href="/search?value1=Erika+Duffell&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Duffell Erika</a>, <a href="/search?value1=Sharon+Hutchinson&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hutchinson Sharon</a>, <a href="/search?value1=Marie+Jauffret-Roustide&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Jauffret-Roustide Marie</a>, <a href="/search?value1=Martin+K%C3%A5berg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kåberg Martin</a>, <a href="/search?value1=Anda+%C4%B6%C4%ABv%C4%ABte-Urt%C4%81ne&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ķīvīte-Urtāne Anda</a>, <a href="/search?value1=Carole+Seguin-Devaux&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Seguin-Devaux Carole</a>, <a href="/search?value1=Vana+Sypsa&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sypsa Vana</a>, <a href="/search?value1=Ruth+Zimmermann&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Zimmermann Ruth</a></span>. Standardising monitoring data on drug-related infectious diseases among people who inject drugs in Europe – an update of the European Union Drugs Agency technical protocol, 2024. <a href="/content/ecdc">Euro Surveill.</a> 2025;30(30):pii=2500007. <a href="https://doi.org/10.2807/1560-7917.ES.2025.30.30.2500007" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2025.30.30.2500007</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 20 Dec 2024;&nbsp;&nbsp; <span class="generated">Accepted</span>: 05 May 2025 </span> </p>
/content/10.2807/1560-7917.ES.2025.30.30.2500007
/content/10.2807/1560-7917.ES.2025.30.30.2500007
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error